Shares of Akari Therapeutics PLC (NASDAQ:AKTX) traded down 29.8% on Thursday . The stock traded as low as $2.01 and last traded at $2.05, 3,675,300 shares traded hands during mid-day trading. An increase of 186% from the average session volume of 1,286,932 shares. The stock had previously closed at $2.92.
Separately, Zacks Investment Research raised Akari Therapeutics from a “strong sell” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Monday, July 1st.
The company has a 50-day simple moving average of $1.95 and a two-hundred day simple moving average of $2.52. The firm has a market cap of $28.00 million, a PE ratio of -12.06 and a beta of -2.81.
Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter. On average, equities analysts expect that Akari Therapeutics PLC will post -1 EPS for the current year.
An institutional investor recently bought a new position in Akari Therapeutics stock. Virtu Financial LLC acquired a new position in Akari Therapeutics PLC (NASDAQ:AKTX) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 39,864 shares of the biopharmaceutical company’s stock, valued at approximately $143,000. Virtu Financial LLC owned about 0.26% of Akari Therapeutics at the end of the most recent quarter. 14.90% of the stock is owned by institutional investors and hedge funds.
Akari Therapeutics Company Profile (NASDAQ:AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.
Recommended Story: Trading Ex-Dividend
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.